热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　康方生物（09926）午前上涨5.53%，现报59.15港元，成交额4.04亿港元。

　　康方生物宣布，公司自主研发的全球首个靶向IL-4Rα/ST2双特异性抗体AK139的新药临床试验申请（IND）已获中国国家药品监督管理局（NMPA）正式受理，针对呼吸系统及皮肤疾病等多领域疾病展开探索。据悉，AK139是康方生物非肿瘤领域首个进入临床阶段的双特异性抗体新药，是公司非肿瘤领域逐步构建全球竞争力的重要组成。此外，AK139也是康方生物第7个进入临床阶段的双抗新药。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.